22 December 2016 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited has completed treatment of all six patients in group 2 of the Phase IIb clinical trial of NTCELL® for Parkinson’s disease, at Auckland City Hospital. Four patients had 80 NTCELL microcapsules implanted into the putamen on each side of their brain, and two patients had sham surgery with no NTCELL implanted. To date there are no safety issues in any of the six patients.
The first five patients in the group were treated between 12 and 19 November. The ability to treat five patients in eight days demonstrates that the company’s internal procedures are working well and the team is meeting the very high standards demanded by the clinical trial protocol.
Melbourne, 13 December 2016 – Venture capital firm Brandon Capital has been selected by the Australian Government to build a significant life sciences fund through the MRCF as part of the new Biomedical Translation Fund (BTF), a once-in-a-generation initiative to make Australia a global leader in the commercialisation of biomedical discoveries.
The government initiative will see more of Australia’s world-class medical research remain in the country to be commercialised, creating jobs, wealth and positive healthcare outcomes for all Australians. Currently, promising Australian medical discoveries are often sold to large offshore pharmaceutical companies at early stages of development due to lack of investment capital available to the sector in Australia. The Commonwealth’s BTF has been designed to address this funding gap.
New Zealand researchers have uncovered a new mechanism that controls the release of the hormone insulin in the body, providing hope for those with a genetic susceptibility to type 2 diabetes.
The findings, which were published today in The Journal of Biological Chemistry1, show for the first time that a protein known as beta-catenin is crucial for controlling the release of insulin from the pancreas to maintain stable blood sugar levels.
AUCKLAND: Patients suffering major burns may eventually benefit from the launch of a new regenerative medicine company, Upside Biotechnologies, which is developing an advanced, world-class skin replacement treatment in Auckland.
Regenerative medicine develops methods to regrow, repair or replace damaged or diseased cells, organs or tissues to restore or establish normal function. The global regenerative medicines market is projected to reach US$30 billion by 2022.
The New Zealand-based company has been spun out of the University of Auckland where the innovative technology was first developed in Professor Rod Dunbar’s laboratory. Work to date has been funded by Cure Kids, Auckland UniServices, the Manchester Trust, the Ministry of Business, Innovation and Employment and The Maurice Wilkins Centre.
Message from the Executive Director of the Exporter
This year we teamed up with DHL to produce the ExportNZ DHL Export Barometer 2016. Thanks to everyone who took part in this important survey.
The results were released this morning. You may have seen them in the media, but if not, see the media release below, along with links to the report on the results and an online booklet covering the highlights.
Some interesting findings in there!
Despite the uncertainties in the world at the moment – such as Brexit and the US election result – exporters are feeling confident for 2017, which is great to hear. There are of course still some barriers to trade that we need to work on, and these results help feed into our work on this.
A Queensland rocket scientist has been awarded the CSL Young Florey Medal for reinventing vaccination.
Australian Institute for Bioengineering and Nanotechnology professor Mark Kendall will be handed the award along with $25,000 in Canberra on Wednesday evening.
The medal is presented every two years by the Australian Institute of Policy and Science to recognise mid-career achievements in biomedical science and human health advancement.
Grasses of the future will make animals healthier, more productive and reduce their impact on the environment.
AgResearch scientist Tony Conner said advances in modern grasses would bring many advantages to farming.
The forage science group leader said the conference was timely given the work the organisation was doing in the area of forage science. He said there were many benefits for New Zealand in building upon the DairyNZ forage value index and the emerging pastoral industry forage strategy.
GMO Answers launched its third annual ‘Get to Know GMOs’ month this October to answer consumers’ most pressing questions about GMOs. Throughout the month, GMO Answers is posting a series of five articles for ‘Get to Know GMOs’ month. This post is our fifth installment.
Dr. Clemente holds the Eugene W. Price Distinguished Professorship in Biotechnology at the University of Nebraska-Lincoln.
My research program at the University of Nebraska-Lincoln, where I have served on the faculty for the past 20 years, targets the genetic improvement of the major commodity crops pertinent to the state and the region, including soybean, sorghum, wheat and corn. The long-term goal of my program is to improve upon both the quality and yield of the harvested crop.